Safe Phototherapy Stop Thresholds for Term and Late Preterm Infants with Hemolytic Disease of Newborn

What this Trial Is About

Researchers are evaluating the safety of different phototherapy stopping points in newborns with hemolytic disease. The study compares a lower threshold versus a higher threshold for stopping phototherapy based on total serum bilirubin TSB levels. The goal is to see which approach reduces the chance of rebound high bilirubin after treatment in term and late preterm infants with this condition. Neonates in the low-threshold group will stop phototherapy when their TSB is about 100 micromolL below the American Academy of Pediatrics AAP threshold. Those in the high-threshold group will stop when TSB is 50 to 100 micromolL below the AAP threshold. Phototherapy is started for both groups according to AAP guidelines, using intensified blue LED lights when TSB reaches treatment levels. Some infants may receive immunoglobulin or exchange transfusions if bilirubin levels are very high or if clinical signs appear. Parents and caregivers can expect close monitoring of their infants through hospital stays, including TSB blood tests and clinical checks. Researchers will track outcomes like rebound high bilirubin within 28 days, length of hospital stay, and any side effects from phototherapy. The study also follows cost of neonatal intensive care over 90 days. Participation lasts during the newborn period with follow-up to assess safety and treatment results.

Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn